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Abstract
BACKGROUND: The risk of febrile seizure is temporarily increased for a few days after the 
administration of certain vaccines in children aged six to 23 months. Our objective was to 
determine the febrile seizure risk following vaccination in children aged one to five months, when 
six different vaccines are typically administered.
METHODS: We identified emergency department visits and inpatient admissions with 
International Classification of Diseases, Ninth Revision, febrile seizure codes among children 
enrolled in nine Vaccine Safety Datalink participating health care organizations from 2006 through 
2011. Febrile seizures were confirmed by medical record abstraction. We used the self-controlled 
risk-interval method to compare the incidence of febrile seizure during postvaccination days 0 to 1 
(risk interval) versus days 14 to 20 (control interval).
RESULTS: We identified 15 febrile seizure cases that occurred after 585,342 vaccination visits. 
The case patients were aged three to five months. The patients had received a median of four 
(range two to six) vaccines simultaneously. The incidence rate ratio of febrile seizure after 
vaccination was 23 (95% confidence interval 5.13 to 100.8), and the attributable risk was 3.92 
(95% confidence interval 1.68 to 6.17) febrile seizure cases per 100,000 persons vaccinated.
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CONCLUSIONS: Vaccination in children aged three to five months was associated with a large 
relative risk of febrile seizure on the day of and the day after vaccination, but the risk was small in 
absolute terms. Postvaccination febrile seizure should not be a concern for the vast majority of 
children receiving vaccines, but clinicians might take this risk into consideration when evaluating 
and treating children susceptible to seizures precipitated by fever.
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Introduction
Febrile seizure is the most common type of seizure in childhood, occurring in up to 5% of 
children.1 Febrile seizure can occur during infections with a variety of pathogens.2,3 Febrile 
seizure has also been associated with certain types of vaccines. The timing of fever and 
febrile seizure after vaccination depends on whether the vaccine contains a live attenuated 
virus, which requires several days to replicate before inducing a febrile response, or contains 
inactivated components, which may elicit a febrile response within the first 24 hours. The 
febrile seizure risk with current US live and inactivated vaccines has been studied in children 
ages six through 23 months, but not in younger children.4,5 The US Advisory Committee on 
Immunization Practices (ACIP) recommends that all children less than six months old 
receive six vaccines to prevent eight infectious diseases.6 There are five inactivated vaccines 
including hepatitis B (HepB) with doses recommended at birth and at one to two months of 
age, and diphtheria-tetanus-acellular pertussis (DTaP), Haemophilus influenzae type b (Hib), 
pneumococcal conjugate (PCV), and inactivated poliovirus (IPV) vaccines with doses 
recommended at two and four months of age. A live attenuated rotavirus (RV) vaccine is 
also recommended at two and four months of age.
The febrile seizure literature reflects a lack of consensus about whether febrile seizure 
should be diagnosed in children less than six months of age. There are three frequently cited 
febrile seizure definitions that list different minimum ages. A National Institutes of Health 
consensus statement published in 1980 described febrile seizure as usually occurring 
between ages 3 months and 5 years.7 In 1993, the International League Against Epilepsy 
defined febrile seizure as occurring in childhood after age one month.8 In 2008, the 
American Academy of Pediatrics published a simple febrile seizure clinical practice 
guideline that defined febrile seizure as occurring in children between ages six and 60 
months.9 That document did not state the rationale for setting the lower age limit at six 
months, but a separate systematic review stated that, in practice, the lower age limit is 
generally considered to be six months because of the concern about serious infections such 
as meningitis presenting with seizure and fever possibly being mistaken for febrile seizure in 
children under six months.10
Our objective was to estimate the febrile seizure risk during the time from vaccination 
through the following day associated with US vaccines administered to children aged one 
through five months.
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Materials and Methods
The Vaccine Safety Datalink (VSD) is a collaboration between the Centers for Disease 
Control and Prevention and several integrated health care organizations (sites) in the United 
States that perform vaccine safety research and surveillance.11 Nine sites contributed data to 
the present study. The VSD population includes over eight million members annually and 
has been shown to be representative of the general US population in terms of demographic 
and socioeconomic variations.12
We identified children in the VSD aged one to five months who had an emergency 
department (ED) visit or inpatient admission from July 1, 2006, through June 30, 2011, 
associated with an International Classification of Diseases, Ninth Revision (ICD-9) 
“convulsion” code (780.3, 780.31, 780.32, or 780.39), which include febrile seizure but not 
epilepsy. We excluded visits that occurred ≤42 days after a previous visit with a convulsion 
ICD-9 code because those are unlikely to represent a new event. We defined the day of 
vaccination as “day 0” and only included convulsion visits that occurred on days zero to one 
or 14 to 20 following the administration of one or more vaccines of any type.
We abstracted medical records to determine whether each patient actually had an incident 
seizure and whether it was accompanied by a fever or not. We defined a “probable” seizure 
as a clinical diagnosis of seizure by the treating physician. We defined a “possible” seizure 
as a paroxysmal event for which the treating physician did not make a definitive diagnosis 
but for which seizure was considered the more likely possibility in the differential diagnosis. 
We defined fever as a temperature of ≥38°C. We defined a febrile seizure as a seizure in a 
child who had a fever within the prior 24 hours, excluding patients with central nervous 
system (CNS) infection, criteria for other symptomatic seizures (e.g., brain structural 
abnormalities and metabolic disturbance), or a history of afebrile seizure.8 Seizures with 
fever that did not meet the febrile seizure definition were classified as “seizure with fever 
other than febrile seizure.”
Statistical methods
We used the self-controlled risk interval (SCRI) method to compare the incidence of febrile 
seizure during the risk interval (zero to one days post vaccination) to the control interval (14 
to 20 days post vaccination).13 The risk interval represents the biologically plausible time 
period during which inactivated vaccines may induce fever. The control interval represents a 
time period during which neither inactivated nor live attenuated vaccines should affect the 
risk of fever or febrile seizure. Comparing two different time intervals for the same 
individual inherently controls for factors that do not change over time. Choosing a control 
interval that is relatively short and close in time to the risk interval implicitly controls for 
factors that change over time, such as age and season. The incidence during each interval 
was calculated by dividing the number of cases by the number of person-days. The 
incidence rate ratio (IRR) with 95% confidence interval (CI) was calculated in SAS 9.4 
using conditional Poisson regression with an offset term to account for the different interval 
lengths.14,15 The attributable risk (AR), which is a measure of the excess number of cases 
that occurred due to exposure to vaccination, was calculated as the difference between the 
risk interval incidence rate and the control interval incidence rate multiplied by two person-
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days (i.e., the duration of the risk interval), and the 95% CI was calculated in OpenEpi using 
the Byar method.16 The primary analysis included only the probable febrile seizure cases.
Institutional review boards at the Centers for Disease Control and Prevention, and each site 
approved the present study and determined that informed consent was not required.
Results
Our study population had 585,342 vaccination visits. Following these, 72 patients had an ED 
or an inpatient visit associated with a convulsion ICD-9 code (30 during the risk interval and 
42 during the control interval). Medical records were available for 65 of these patients (Fig). 
There were 31 patients with probable seizures, including 11 seizures without fever, 15 
febrile seizures, and five seizures with fever other than febrile seizure. Among the seizures 
with fever other than febrile seizure, three had a history of prior afebrile seizure and two 
were originally diagnosed as febrile seizure but were later diagnosed with epilepsy following 
subsequent afebrile seizures. There were nine patients with possible seizures, among which 
were five seizures without fever and four febrile seizures.
The characteristics of the patients with febrile seizure are shown in Table 1. The probable 
febrile seizures all occurred in children aged three to five months, whereas the possible 
febrile seizures occurred from one to four months of age. The reported seizure duration 
ranged from five seconds to five minutes. The seizure was witnessed by a heath care 
provider in only two instances. The provider notes used the term “febrile seizure” to label 
the diagnosis in 12 of the patients. Six case patients had a non-CNS infection documented at 
the time the seizure was evaluated (three with upper respiratory tract infection, one with 
upper respiratory tract infection and acute otitis media, one with sinusitis, and one with 
pyelonephritis).
The 19 probable or possible febrile seizure case patients received a median of four vaccines 
(range two to six) on day 0 before the febrile seizure (Table 1). Eighteen patients (95%) 
received PCV, and 17 patients (90%) received a “DTaP-containing” combination vaccine 
(i.e., DTaP-HepB-IPV or “DTaP-IPV/Hib”). Twelve case patients (63%) received all six 
recommended vaccine types (Table 2).
Table 3 shows the incidence of probable febrile seizure following vaccination by age in 
months. The IRR of probable febrile seizure was 23 (95% CI 5.13 to 100.8), and the AR was 
3.92 (95% CI 1.68 to 6.17) febrile seizure cases per 100,000 children vaccinated at ages 3 to 
5 months. When both probable and possible febrile seizure cases were combined, the IRR 
was 13 (95% CI 4.36 to 39.6), and the AR was 2.37 (95% CI 1.06 to 3.68) febrile seizure 
cases per 100,000 children vaccinated at ages one to five months.
Table 4 shows results of additional SCRI analyses. When case patients with a non-CNS 
infection at the time of the seizure were excluded, the febrile seizure risk after vaccination 
was still significantly increased. The IRR was also significantly increased when all seizures 
with fever were included in the analysis. However, in an analysis of only seizure without 
fever, the IRR was not significantly increased at 2.0 (95% CI 0.59 to 6.83).
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Discussion
Seizures with fever that met the definition of probable febrile seizure occurred after 
vaccination in children aged three to five months (and possible febrile seizures also occurred 
in children ages one to two months). The majority of these seizures were labeled as febrile 
seizure in routine clinical practice, even after the publication of a US clinical practice 
guideline that stated the lower age limit for febrile seizure to be six months.9 The relative 
risk of febrile seizure occurring on the day of vaccination or on the day after vaccination was 
high in this age group, but in absolute terms, the number of febrile seizures attributable to 
vaccination was 3.92 cases per 100,000 infants vaccinated. This AR is similar to previous 
estimates for certain vaccines given at ages six or 12 months.4
In this study, all vaccines received by the case patients were age appropriate, except for one 
child who received influenza vaccine at age five months, which is less than the minimum 
recommended age of six months. The most common combination of vaccines received 
simultaneously by patients in the present study was RV5, DTaP-HepB-IPV, Hib, and PCV. 
This combination includes all six of the vaccine types recommended in this age range, which 
the ACIP recommendations state may all be given together. This combination of vaccines 
was associated with an increased risk of febrile seizure in a subgroup analysis. We could not 
evaluate the risk associated with other specific vaccine combinations due to the small 
number of individuals who received them, nor could we evaluate the febrile seizure risk 
associated with individual vaccines, because all but one of the febrile seizure case patients 
had received PCV. PCV was independently associated with an increased risk of febrile 
seizure among children ages six to 23 months in a recent VSD study.4 In the current study, 
we cannot determine if the risk observed is due to PCV alone or if other individual vaccines 
or interactions between vaccines contributed to the observed risk because we did not have 
enough children who did not receive PCV for comparison.
Several previous studies that sought to examine febrile seizure risk after individual vaccines 
also included children less than six months old. “Diphtheria-tetanus-whole-cell” pertussis 
vaccines, which are no longer used in the United States, were associated with an increased 
febrile seizure risk in several studies. A VSD study of diphtheria–tetanus-whole-cell 
pertussis during the period from 1991 through 1993 found an AR of six to nine febrile 
seizures per 100,000 children on the day of vaccination.17 That study included all children 
under age seven years but did not report age specific results. Two studies of whole-cell 
pertussis vaccines in the United Kingdom also found an increased febrile seizure risk, but 
the first found no increased risk in children less than six months old, whereas the second did 
not report results specific to this age group.14,18 Whole-cell pertussis vaccines were replaced 
with acellular pertussis vaccines in the United States in the 1990s. A VSD study of DTaP 
vaccines (given with or without simultaneous vaccines) during the period from 1997 to 2006 
found no increase in seizure risk during the zero to three days postvaccination in children 
ages six weeks to 23 months, including dose-specific results applicable to children less than 
six months old.19 The reason why our current study, in which 90% of case patients received 
a DTaP-containing vaccine, observed an increased febrile seizure risk whereas the DTaP 
study did not could be due to study design differences or differences in the vaccines included 
in the studies. The previous study relied on ICD-9 codes without medical record abstraction 
Duffy et al. Page 5
Pediatr Neurol. Author manuscript; available in PMC 2019 July 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and did not analyze febrile seizure separately from other types of seizure. The vaccines 
available and recommended during the previous study’s period were different from the 
current immunization schedule; PCV and DTaP-HepB-IPV were not yet licensed during the 
earlier part of that study period. In clinical trials, DTaP-HepB-IPV had higher rates of fever 
compared with its separately administered component vaccines.20 So the large percentage of 
case patients in the current study who received PCV or DTaP-HepB-IPV might account for 
the increased risk we observed. A different DTaP combination vaccine was associated with 
increased febrile seizure risk specifically in children less than six months of age in another 
study. A DTaP-IPV-Hib combination vaccine manufactured by the Statens Serum Institut, 
which is not licensed in the United States, was studied in Denmark from 2003 to 2008, and 
there was an increased febrile seizure risk on the day of vaccination at ages 3 and 5 months.
21
 The absolute risk was less than 4 per 100,000 persons. PCV was not used during most of 
that study period and did not account for that finding.
Our results indicate that febrile seizure risk may increase on the day of or the day after 
administration of an inactivated vaccine, but not all febrile seizures occurring during this 
time interval will necessarily be caused by vaccination. In our study, 32% of patients with a 
febrile seizure during the risk interval after vaccination had a non-CNS infection 
documented at the time of their febrile seizure, which may have led to or contributed to the 
febrile seizure. Some of these seizures may also be due to noninfectious preexisting 
conditions that have not yet been diagnosed. A study in The Netherlands of children under 
two years old who experienced seizures following vaccination (including but not limited to 
febrile seizure) found that 4.5% were diagnosed with epilepsy by age two years.22 In more 
than half of the children with epilepsy, the first seizure had occurred in temporal association 
with vaccination. In those whose epilepsy onset had been temporally associated with 
vaccination, 65% had an identifiable genetic or structural cause. Genetic mutations have 
been associated with epilepsy syndromes characterized by seizures with fever such as Dravet 
syndrome (also known as severe myoclonic epilepsy of infancy) and generalized epilepsy 
with febrile seizures plus.23 These syndromes may not be recognized at the time of the first 
seizure. In our study, two patients who initially had a seizure with fever went on to later have 
afebrile seizures and be diagnosed with epilepsy. So perhaps the diagnosis of an apparent 
febrile seizure in a child under six months who has a seizure with fever should be considered 
a provisional diagnosis, with the recognition that the diagnosis might change as the child 
ages and additional syndromic features present. Our secondary analysis that included all 
seizures with fever also revealed a significantly increased risk, which could suggest an 
increased risk of epileptic seizure precipitated by fever following vaccination regardless of 
the underlying mechanism of seizure susceptibility. In as much as certain types of vaccine 
may elicit fever, and fever in turn may precipitate a seizure in susceptible individuals, this 
would not be surprising.
This study had several potential limitations. First, we searched only for patients with ED 
visits or inpatient admissions because a prior VSD study of postvaccination ICD-9 code 
chart confirmation rates in children ages six weeks to 23 months found that clinic visits with 
the convulsion codes rarely represent true incident seizures, particularly in children less than 
one year old.24 So there might have been a few additional febrile seizure case patients seen 
only in the clinic setting who were not included in our study. Not including such patients 
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would result in a slight underestimation of the incidence rate, but would not affect the IRR 
estimates derived from the SCRI method, which does not require the capture of all cases in 
the source population. Second, postvaccination febrile seizure is a rare event, so despite our 
large study population, our analysis is based on a relatively small number of cases, 
particularly in the control interval. This led to fairly wide CIs around some of our risk 
estimates. Third, the present study relied on the treating physician’s clinical diagnosis of a 
seizure as documented in the medical record. The clinical notes rarely contained detailed 
descriptions of seizure signs and symptoms needed to utilize the Brighton Collaboration 
generalized convulsive seizure definition, which is a standardized case definition that was 
developed for vaccine safety studies.25 Most of the paroxysmal events were not witnessed by 
a health care provider, and the physician did not make a definitive diagnosis for 31% of the 
patients. We accounted for this uncertainty by defining a category of possible seizure in our 
case classification scheme and excluded the possible cases from the primary analysis. 
Fourth, the present study focused on a risk interval appropriate for febrile seizure risk with 
inactivated vaccines, which may not be an appropriate risk interval for studying febrile 
seizure following live-attenuated RV vaccine. Pentavalent (RV5) was the only RV vaccine 
received by patients in the present study. The rate of fever following RV5 in clinical trials 
was not higher than placebo, so the likelihood of an acute febrile seizure risk with RV5 is 
probably low.26
The vaccine products included in the present study are still available and in use today. The 
ACIP recommendations for routine immunization of children in the one- to five month age 
range in effect during this study period are the same as the current ACIP recommendations. 
Therefore, the present study represents the best estimate of the risk of febrile seizure 
associated with the current US immunization schedule for children ages 1 to 5 months. The 
AR of febrile seizure following vaccination in this age range is small. Therefore, 
postvaccination febrile seizure should not be a concern for the vast majority of children 
receiving vaccines, but clinicians might take this risk into consideration when evaluating and 
treating children susceptible to seizures precipitated by fever.
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FIGURE. 
Case classification based on medical record abstraction for patients ages 1 to 5 months who 
had a medical visit with an International Classification of Diseases, Ninth Revision 
“convulsion” code during specified time intervals following vaccination. The total number of 
patients is shown first followed in parentheses by the number of patients whose events 
occurred during the risk interval and the control interval, respectively. The risk interval was 
postvaccination days 0 to 1 and the control interval was postvaccination days 14 to 20. CNS, 
central nervous system; FS, febrile seizure.
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TABLE 2.
Simultaneous Vaccination Combinations Received on Day 0 by Case Patients With a Probable or Possible 
Febrile Seizure Following Vaccination
Cases, n Simultaneous Vaccination Combinations
12 RV5 DTaP-HepB-IPV Hib PCV
2 DTaP-HepB-IPV Hib PCV
1 RV5 DTaP-IPV/Hib PCV HepB IIV3 MIV
1 RV5 DTaP-IPV/Hib PCV
1 RV5 DTaP-IPV/Hib
1 RV5 Hib PCV
1 Hib PCV
Abbreviations:
DTaP = Diphtheria-tetanus-acellular pertussis
HepB = Hepatitis B
Hib = Haemophilus influenzae type b
IIV3 = Inactivated influenza vaccine trivalent
IPV = Inactivated poliovirus
MIV = Monovalent pandemic 2009 H1N1 inactivated influenza vaccine
PCV = Pneumococcal conjugate
RV5 = Rotavirus vaccine pentavalent
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TABLE 3.
Number of Probable Febrile Seizure Cases and Incidence Rate Following Vaccination by Age in Months
Age (Months) Vaccination Visits Patients With “Convulsion” ICD-9 Code Probable Febrile Seizure Cases
Risk Interval, n (Rate*) Control Interval, n (Rate*)
1 67,477 5 0 0
2 200,998 15 0 0
3 61,369 14 4(3.26) 0
4 202,299 34 7 (1.73) 2 (0.14)
5 53,199 4 2 (1.88) 0
TOTAL 585,342 72 13 (1.11) 2 (0.05)
Abbreviations:
ICD-9 = International Classification of Diseases, Ninth Revision
*
Incidence rate is per 100,000 person-days.
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